{
    "clinical_study": {
        "@rank": "13163", 
        "arm_group": [
            {
                "arm_group_label": "Iron-fortified dairy product", 
                "arm_group_type": "Experimental", 
                "description": "Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet"
            }, 
            {
                "arm_group_label": "Iron and vitamin D dairy product", 
                "arm_group_type": "Experimental", 
                "description": "Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet"
            }
        ], 
        "brief_summary": {
            "textblock": "Iron deficiency and vitamin D deficiencies are common in menstruating women. The present\n      assay studied the influence of the consumption of a flavoured skimmed milk with iron (iron\n      pyrophosphate) or with iron and vitamin D3 in iron deficient women on:\n\n        -  Iron metabolism\n\n        -  Biomarkers of bone remodelling\n\n        -  Cardiovascular risk indexes"
        }, 
        "brief_title": "Iron-fortified Flavoured Skimmed Milk With or Without Vitamin D in Iron Deficient Women", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Iron Deficiency", 
        "condition_browse": {
            "mesh_term": "Anemia, Iron-Deficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-smoker or smokers of \u2264 3 cigarettes/day\n\n          -  Non-pregnant\n\n          -  non-breast-feeding\n\n          -  Serum ferritin <30ng/mL\n\n          -  Haemoglobin \u226511g/dL\n\n        Exclusion Criteria:\n\n          -  Amenorrhea\n\n          -  Menopause\n\n          -  Any known health problems likely to influence iron status including\n             iron-metabolism-related diseases (iron deficiency anaemia, thalassaemia,\n             haemochromatosis)\n\n          -  Chronic gastric diseases (inflammatory bowel disease, Crohn disease, gastric ulcers,\n             celiac disease, hemorrhagic diseases)\n\n          -  Renal disease or allergy to some of the components of the assay diary product.\n\n          -  Blood donors\n\n          -  Have regularly consumed iron or ascorbic acid supplements within the four months\n             prior to participating in the intervention."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739907", 
            "org_study_id": "AGL2009-11437"
        }, 
        "intervention": {
            "arm_group_label": [
                "Iron-fortified dairy product", 
                "Iron and vitamin D dairy product"
            ], 
            "intervention_name": "Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Iron deficiency", 
            "Menstruating women", 
            "Vitamin D", 
            "Functional food"
        ], 
        "lastchanged_date": "July 19, 2013", 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Ferritin changes over 16 weeks", 
            "safety_issue": "No", 
            "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739907"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Research Council, Spain", 
            "investigator_full_name": "M Pilar Vaquero", 
            "investigator_title": "Scientific researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Haemoglobin changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Total erythrocytes changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Haematocrit changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Mean corpuscular volume changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Red blood cell distribution width changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Serum iron changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Serum transferrin changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Transferrin saturation changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 4, 8, 12 and 16 weeks)"
            }, 
            {
                "measure": "Soluble transferrin receptor changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8, and 16 weeks)"
            }, 
            {
                "measure": "25-hydroxyvitamin D changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8, and 16 weeks)"
            }, 
            {
                "measure": "Procollagen type 1 N-terminal propeptide (P1NP) changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "Cross-linked N-telopeptides of type I collagen (NTX) changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (measures at 0, 8 and 16 weeks"
            }, 
            {
                "measure": "Parathormone (PTH) changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (measures at 0, 8 and 16 weeks"
            }, 
            {
                "measure": "Total cholesterol changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks"
            }, 
            {
                "measure": "LDL-cholesterol changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "HDL-cholesterol changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "Triglycerides changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "Systolic blood pressure changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "Diastolic blood pressure changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }, 
            {
                "measure": "glucose changes over 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks (Measures at 0, 8 and 16 weeks)"
            }
        ], 
        "source": "National Research Council, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Research Council, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}